Ligand Pharmaceuticals (LGND) Cost of Revenue (2011 - 2026)

Ligand Pharmaceuticals' Cost of Revenue history runs 16 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• In Q1 2026, Cost of Revenue fell 32.5% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $13.0 million (down 0.52% YoY), while the FY2025 annual figure was $14.5 million, up 31.38% from the prior year.
• Cost of Revenue came in at $3.3 million for Q1 2026 at Ligand Pharmaceuticals, up from $3.0 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $21.6 million in Q4 2022 to a low of $1.6 million in Q4 2023.
• A 5-year average of $5.4 million and a median of $3.3 million in 2026 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue surged 80.36% in 2022 and plunged 92.41% in 2023, its largest moves.
• Ligand Pharmaceuticals' Cost of Revenue stood at $21.6 million in 2022, then slumped by 92.41% to $1.6 million in 2023, then jumped by 72.88% to $2.8 million in 2024, then climbed by 5.46% to $3.0 million in 2025, then advanced by 9.39% to $3.3 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $3.3 million, $3.0 million, and $3.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison